Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes

Carl D D'Ruiz, Donald W Graff, Edward Robinson, Carl D D'Ruiz, Donald W Graff, Edward Robinson

Abstract

Background: Electronic cigarettes (e-cigarettes) are popular alternatives to conventional cigarettes among adult smokers wishing to reduce their exposure to harmful smoke constituents. However, little information exists on the relative internal exposures resulting from the exclusive or dual use of e-cigarettes.

Methods: Measurements of product use; adverse events; changes in smoking urge; and blood, urine and exhaled breath biomarkers of exposure (BoE) representing toxicants believed to contribute to smoking related diseases were made at baseline and after five days of product use in 105 clinically-confined smokers randomized into groups that partially or completely substituted their usual brand combustible cigarette with commercial e-cigarettes, or discontinued all nicotine and tobacco products.

Results: Subjects switching to e-cigarettes had significantly lower levels (29 %-95 %) of urinary BoEs after 5 days. Nicotine equivalents declined by 25 %-40 %. Dual users who substituted half of their self-reported daily cigarette consumption with e-cigarettes experienced 7 %-38 % reductions, but had increases (1 %-20 %) in nicotine equivalents. Blood nicotine biomarker levels were lower in the cessation (75 %-96 %) and e-cigarette use groups (11 %-83 %); dual users had no significant reductions. All groups experienced significant decreases in exhaled CO (27 %-89 %). Exhaled NO increases (46 %-63 %) were observed in the cessation and e-cigarette use groups; dual users had minimal changes. By Day 5, all groups had greater reductions in smoking urge compared to cessation. However, reductions were larger in the dual use group. No serious adverse events were observed.

Conclusions: Exposures to harmful smoke toxicants were observed to be lower in smokers who completely or partially replaced their cigarettes with e-cigarettes over five days.

Trial registration: ClinicalTrials.gov NCT02385227.

Keywords: Adverse events; Biomarkers of exposure; Clinical trial; Electronic cigarettes; Exclusive and dual use; Nicotine cessation; Urge to smoke.

Figures

Fig. 1
Fig. 1
Urine biomarkers - Day 5 % change from Day −1
Fig. 2
Fig. 2
Blood biomarkers - Day 5 % change from Day −1
Fig. 3
Fig. 3
Exhaled Breath Biomarkers - Day 5 % Change from Day −1

References

    1. U.S. Department of Health and Human Services . National center for chronic disease prevention and health promotion, office on smoking and health: the health consequences of smoking – 50 years of progress: a report of the surgeon general. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention (DHHS), National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
    1. Jamal A, Agaku IT, O’Connor E, King BA, Kenemer JB, Neff L. Current cigarette smoking among adults—United States, 2005–2013. MMWR Morb Mortal Wkly Rep. 2014;63(47):1108–1112.
    1. Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control: a step forward or a repeat of past mistakes. J Public Health Pol. 2011;32(1):16–31. doi: 10.1057/jphp.2010.41.
    1. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rosik-Dulewska C, Havel C. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23:133–139. doi: 10.1136/tobaccocontrol-2012-050859.
    1. Hajek P, Etter J-F, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014;109(11):1801–10. doi: 10.1111/add.12659.
    1. Burstyn I. Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health. 2014;14(1):18. doi: 10.1186/1471-2458-14-18.
    1. Polosa R, Rodu B, Caponnetto P, Maglia M, Raciti C. A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Red J. 2013;10(1):19. doi: 10.1186/1477-7517-10-19.
    1. Tayyarah R. Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air. Reg Tox Pharma. 2014;70(3):704–10. doi: 10.1016/j.yrtph.2014.10.010.
    1. Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Safety. 2014;5(2):67–86. doi: 10.1177/2042098614524430.
    1. Pepper JK, Brewer NT. 2013. Electronic nicotine delivery system (electronic cigarette) awareness, use, reactions and beliefs: A systematic review. Tob Control. 2014;23(5):375–84. doi: 10.1136/tobaccocontrol-2013-051122.
    1. Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. Int J Environ Res Public Health. 2014;11(4):4356–4373. doi: 10.3390/ijerph110404356.
    1. McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD010216. DOI: 10.1002/14651858.CD010216.pub2.
    1. Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, Kramarczuk I, Roe MR, Puumala SS, Li YS, Le C, Jensen J, Hatsukami DK. Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst. 2004;96(2):107–115. doi: 10.1093/jnci/djh016.
    1. McRobbie H, Phillips A, Goniewicz ML, Smith KM, Knight-West O, Przulj D, Hajek P. Effects of switching to electronic cigarettes with and without concurrent smoking on exposure to nicotine, carbon monoxide, and acrolein. Cancer Prev Res. 2015;8(9):873–878. doi: 10.1158/1940-6207.CAPR-15-0058.
    1. Hecht SS, Yuan J-M, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Tox. 2010;23(6):1001–1008. doi: 10.1021/tx100056m.
    1. Gregg EO, Minet E, McEwan M. Urinary biomarkers of smokers’ exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers. 2013;18(6):467–486. doi: 10.3109/1354750X.2013.821523.
    1. Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D, Russo C. Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health. 2011;11(1):786. doi: 10.1186/1471-2458-11-786.
    1. Hecht SS, Yuan J-M, Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Toxicant Biomarkers Product Regulation Cancer Prev Chem Res Tox. 2010;23(6):1001–1008.
    1. Carmella SG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, Hecht SS. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicology. 2009;22(4):734–741. doi: 10.1021/tx800479s.
    1. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis. 2002;23(6):907–922. doi: 10.1093/carcin/23.6.907.
    1. Deveci SE, Deveci F, Açik Y, Ozan AT. The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Resp Med. 2004;98(6):551–556. doi: 10.1016/j.rmed.2003.11.018.
    1. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Amer J Resp Criti Care Med. 1995;152(2):609–612. doi: 10.1164/ajrccm.152.2.7543345.
    1. D’Ruiz CD, Graff DW, Yan XS. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes. BMC Public Health. 2015;15:991. doi: 10.1186/s12889-015-2349-2.
    1. Hecht SS, Carmella SG, Chen M, Koch JFD, Miller AT, Murphy SE, Jensen JA, Zimmerman CL, Hatsukami DK. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res. 1999;59(3):590–596.
    1. Sarkar M, Liu J, Koval T, Wang J, Feng S, Serafin R, Jin Y, Xie Y, Newland K, Roethig HJ. Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. Nicotine Tob Res. 2010;12(2):105–116. doi: 10.1093/ntr/ntp183.
    1. Heatherton TF, Kozlowski LT, Frecker RC, FAGERSTROM KO. The fagerström test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. British J Addiction. 1991;86(9):1119–1127. doi: 10.1111/j.1360-0443.1991.tb01879.x.
    1. Fagerström K. Determinants of tobacco use and renaming the FTND to the fagerström test for cigarette dependence. Nicotine Tob Res. 2012;14(1):75–78. doi: 10.1093/ntr/ntr137.
    1. Jarvis JM, Rusell MAH, Saloojee Y. Expired air carbon monoxide: a simple breath test of tobacco smoke intake. BMJ. 1980;2:484. doi: 10.1136/bmj.281.6238.484.
    1. Ripoll J, Girauta H, Ramos M, et al. Clinical trial on the efficacy of exhaled carbon monoxide measurement in smoking cessation in primary health care. BMC Public Health. 2012;12:322. doi: 10.1186/1471-2458-12-322.
    1. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100:299–303. doi: 10.1111/j.1360-0443.2004.00995.x.
    1. Yates DH, Breen H, Thomas PS. Passive smoke inhalation decreases exhaled nitric oxide in normal subjects. Am J Respir Crit Care Med. 2001;164(6):1043–6. doi: 10.1164/ajrccm.164.6.2005043.
    1. Hogman M, Holmkvist T, Walinder R, Merilainen P, Ludviksdottir D, Hakansson L, Hedenstrom H. Increased nitric oxide elimination from the airways after smoking cessation. Clin Sci (Lond) 2002;103(1):15–9. doi: 10.1042/cs1030015.
    1. Robbins RA, Millatmal T, Lassi K, Rennard S, Daughton D. Smoking cessation is associated with an increase in exhaled nitric oxide. Chest. 1997;112(2):313–8. doi: 10.1378/chest.112.2.313.
    1. Malinovschi A, Janson C, Holmkvist T, Norbäck D, Meriläinen P, Högman M. Effect of smoking on exhaled nitric oxide and flow-independent nitric oxide exchange parameters. Eur Respir J. 2006;28(2):339–45. doi: 10.1183/09031936.06.00113705.
    1. Chambers DC, Tunnicliffe WS, Ayres JG. Acute inhalation of cigarette smoke increases lower respiratory tract nitric oxide concentrations. Thorax. 1998;53(8):677–9. doi: 10.1136/thx.53.8.677.
    1. Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health. 2013;10(2):446–461. doi: 10.3390/ijerph10020446.
    1. Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidem Biomar. 2010;19(8):1945–1953. doi: 10.1158/1055-9965.EPI-10-0288.
    1. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V: Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci Rep. 2014;4:4133.
    1. Yan XS, D’Ruiz C. Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Reg Tox Pharma. 2015;71(1):24–34. doi: 10.1016/j.yrtph.2014.11.004.
    1. Hecht SS, Carmella SG, Kotandeniya D, Pillsbury ME, Chen M, Ransom BWS, Vogel RI, Thompson E, Murphy SE, Hatsukami DK. Evaluation of toxicant and carcinogen metabolites in the urine of E-cigarette users versus cigarette smokers. Nicotine Tob Res. 2015;17(6):704–709. doi: 10.1093/ntr/ntu218.
    1. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation. 2014;129(19):1972–86. doi: 10.1161/CIRCULATIONAHA.114.007667.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel